|
CENPK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.76180198102816E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.72952796318305E-12 |
| Normal-vs-Stage2 |
1.158780E-03 |
| Normal-vs-Stage3 |
4.25399999670617E-08 |
| Normal-vs-Stage4 |
2.89669999997688E-06 |
| Stage1-vs-Stage2 |
3.204400E-04 |
| Stage1-vs-Stage3 |
3.945000E-01 |
| Stage1-vs-Stage4 |
5.580000E-01 |
| Stage2-vs-Stage3 |
1.307980E-02 |
| Stage2-vs-Stage4 |
4.530000E-02 |
| Stage3-vs-Stage4 |
9.638600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02250430344952E-11 |
| Normal-vs-AfricanAmerican |
5.562300E-04 |
| Normal-vs-Asian |
1.42029999983251E-07 |
| Caucasian-vs-AfricanAmerican |
3.172400E-01 |
| Caucasian-vs-Asian |
7.734800E-01 |
| AfricanAmerican-vs-Asian |
4.445400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.87839974077997E-10 |
| Normal-vs-Female |
4.8744996927752E-10 |
| Male-vs-Female |
3.586600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.67597055625401E-12 |
| Normal-vs-Age(41-60Yrs) |
1.30889999949702E-07 |
| Normal-vs-Age(61-80Yrs) |
3.58519999998919E-06 |
| Normal-vs-Age(81-100Yrs) |
3.009500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.428700E-04 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.763730E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.092200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.048800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.885550E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.622170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.107500E-02 |
| Classical-VS-Follicular |
3.143900E-03 |
| Classical-VS-Other |
5.297600E-01 |
| Classical-VS-Normal |
5.49393863735759E-12 |
| Tall-VS-Follicular |
5.952700E-04 |
| Tall-VS-Other |
1.218420E-01 |
| Tall-VS-Normal |
2.19529949774255E-10 |
| Follicular-VS-Other |
7.184800E-01 |
| Follicular-VS-Normal |
8.40699999999917E-05 |
| Other-VS-Normal |
1.799760E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.36399999470538E-08 |
| Normal-vs-N1 |
1.00239999967222E-07 |
| N0-vs-N1 |
1.522240E-01 |
|
|
